🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

59 results for “Vera” Clear

  1. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

    phase 2 small molecule active

    1 trial

  2. Atacicept 150 mg

    Vera Therapeutics

    IgA Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  3. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Multiple Autoimmune Glomerular Diseases

    phase 2 small molecule active

    1 trial

  4. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Treatment of IgAN

    phase 2 small molecule active

    1 trial

  5. Capecitabine

    Vera Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  6. DISC-3405

    Disc Medicine

    Polycythemia Vera (PV)

    phase 2 small molecule active

    1 trial

  7. EXENATIDE , VERAPAMIL

    Disc Medicine

    type 1 diabetes mellitus

    phase 2 small molecule active

    1 trial

  8. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline Biologicals S.A.

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  9. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  10. ISIS 702843

    IONIS PHARMACEUTICALS INC

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  11. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  12. NestaCell®

    Vera Therapeutics

    COVID-19 Pneumonia

    phase 2 mab completed

    1 trial

  13. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  14. PTG-300

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 2 small molecule completed

    2 trials

  15. SLN124

    Silence Therapeutics plc

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  16. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  17. lestaurtinib

    Teva Pharma GmbH

    Polycythemia Vera

    phase 2 small molecule completed

    1 trial

  18. sapablursen

    IONIS PHARMACEUTICALS INC

    Phlebotomy Dependent Polycythemia Vera

    phase 2 small molecule active

    1 trial

  19. A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  20. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  21. Alcohol + Caffeine Beverage

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol or Other Drugs Effects

    phase 1 small molecule completed

    1 trial

  22. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Ste

    Pharma Mar S.A.

    Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-disease.

    phase 1 other active

    1 trial

  23. PRT12396

    Prelude Therapeutics Inc

    Polycythemia Vera (PV)

    phase 1 small molecule active

    1 trial

  24. riliprubart

    Vera Therapeutics

    Autoimmune haemolytic anaemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources